CFS
MRKR icon

CRA Financial Services’s Marker Therapeutics MRKR Stock Holding History

CRA Financial Services’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,150
Closed -$3.06K – 208
2022
Q4 		$3.06K Hold
1,150
– – ﹤0.01% 204
2022
Q3 		$4K Hold
1,150
– – ﹤0.01% 191
2022
Q2 		$4K Hold
1,150
– – ﹤0.01% 203
2022
Q1 		$5K Hold
1,150
– – ﹤0.01% 207
2021
Q4 		$11K Buy
1,150
+2
+0.2% +$27 ﹤0.01% 205
2021
Q3 		$19K Buy
+1,148
New +$23.5K 0.01% 196

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CRA Financial Services's MRKR Position: Q1 2023 in Review

CRA Financial Services sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 1,150 shares — an estimated $3.06K sold.

CRA Financial Services first reported a position in MRKR in Q3 2021 and held it in 6 quarters. The position peaked at $19K in Q3 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • CRA Financial Services reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CRA Financial Services sold 1,150 Marker Therapeutics shares in Q1 2023, an estimated $3.06K.
  • CRA Financial Services first reported a position in Marker Therapeutics in Q3 2021 and held it in 6 quarters.
  • CRA Financial Services's Marker Therapeutics position peaked at $19K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on CRA Financial Services's 13F filing for Q1 2023, filed 6 Apr 2023.